Anti-inflammatory therapies for bronchopulmonary dysplasia

Paris Clarice Papagianis

Research output: ThesisDoctoral Thesis

584 Downloads (Pure)

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that represents the principal cause of morbidity in extremely preterm infants. There is no therapy for BPD.
'BPD is defined as the requirement for respiratory support for at least 28 days. BPD is characterised by lung inflammation. Prevention or attenuation of inflammation offers a realistic therapeutic for BPD.
We utilised low-dose postnatal steroids and human amnion epithelial cells (hAECs) in separate studies to prevent inflammation and BPD-like pathology in preterm lambs. We show low-dose postnatal steroids reduce lung inflammation, while hAECs augment lung inflammation. Neither therapy reduced ventilator requirements in preterm lambs.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • The University of Western Australia
Thesis sponsors
Award date15 Feb 2019
DOIs
Publication statusUnpublished - 2019

Fingerprint Dive into the research topics of 'Anti-inflammatory therapies for bronchopulmonary dysplasia'. Together they form a unique fingerprint.

Cite this